11 result(s) for 'Multiplex'
1 - 10 of 11 results for 'Multiplex'
Sort by
Show
Current technology allows tumors to be painted with multiple colors, termed multiplex staining. Multiplex staining today used in research, may also assist with cancer diagnoses clinically via: preservation of tissue, improved diagnostic accuracy, and enhanced diagnostic insight.
The content of this webinar will encompass detailed technical descriptions of novel and state of the art methods to decalcify tissue samples that will be embedded in paraffin or for frozen sectioning for molecular and nucleic acid analysis for basic research...
In recent years, digital pathology has gone from an intriguing idea to an integral part of how academic and commercial labs operate. Join Leica Biosystems and Procia Digital Pathology as they discuss why institutions are going digital today and how they...
Michael Surace is a scientist at AstraZeneca, where he is responsible for the design, optimization, and validation of multiplex IF panels, as well as imaging and image analysis approaches specifically for the discovery of complex predicitive and prognostic biomarkers for immune oncology.
Carlee Hemphill is a Lead Scientist I at the Covance CDx laboratory in RTP, NC with a background in histology, anatomical pathology and bioinformatics. Her current role is the development of IHC or multiplex immuno florescence assays, or computational pathology algorithms, for clients interested in a complementary or companion diagnostic testing assay for their immuo-oncology pharmaceutical drug development pipeline.
Chifei is a senior histotechnologist with GSK R&D. He has broad knowledge and technical skills in routine histology, immunohistochemistry, multiplex immunofluorescence, digital pathology and quantitative image analysis. His work scopes from target validation, animal model characterization to clinical biomarker assay development and validation. He has a master’s degree in neurobiology from Fudan University and a bachelor’s degree in biology from Shandong University in China.
Dean joined Leica Biosystems in 2016 and is a senior scientist in the R&D team in Melbourne, working on advanced staining projects. He graduated from Monash University where he pursued a PhD, with the department of Immunology and Pathology. During this time, he investigated the role of T cell lineages in mediating inflammatory retinal disorders. He assessed cellular interactions using fluorescent multiplex IHC with confocal microscopy imaging of retinal wholemounts.
Tom is the Manager of Product Technology & Strategy at Leica Biosystems. He is currently leading Spatial Profiling new product development focusing on making clinical impacts. He came to LBS three years ago as a Principal Scientist supporting multiplex assay expansion strategies. Tom has been in the IVD industry for 15+ years; he holds a B.S. in Chemistry from Haverford College, a Ph.D. in Chemistry from Duke University and completed postdoctoral studies in Chemical Engineering at the Massachusetts Institute of Technology.
Charlotte Gray is an Applications Consultant at Leica Biosystems in the UK, specializing in advanced staining with a particular interest in life science applications. Charlotte has a decade of experience after graduating from the University of Nottingham with a BSc (Hons) Medical Science degree. She started her career as an HCPC registered Biomedical Scientist in the NHS working in Histology and was the lead for her trust’s involvement in the 100,000 Genomes Project. Charlotte then worked at the University of Birmingham as Tissue Services Manager and was responsible for managing a research Histology lab, implementing multiplex IHC/ISH, and contributing to digital analysis. During her time at the university, she completed her MSc in Genomic Medicine degree. Charlotte has interes...
Stephanie is a Lecturer in Precision Medicine at the Patrick G. Johnson Centre for Cancer Research, Queen’s University Belfast. She has a breath of experience in the application and validation of translational cancer research methodologies using molecular pathology techniques (immunohistochemistry, in situ hybridisation, multiplex immunofluorescence) and statistics. Her research focuses on predictive biomarker studies and understanding confounding variables that influence the prediction of poor prognosis subgroups in cancer research including reproducible study design, choice of molecular test and assessment criteria.